Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Neoplasia. 2010 Dec;12(12):993-1002. doi: 10.1593/neo.101044.
Microinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered within the fallopian tube of BRCA1 mutation carriers at the time of risk-reducing salpingo-oophorectomy, suggesting that many BRCA1-mutated ovarian carcinomas originate in tubal epithelium. We hypothesized that changes in gene expression profiles within the histologically normal fallopian tube epithelium of BRCA1 mutation carriers would overlap with the expression profiles in BRCA1-mutated ovarian carcinomas and represent a BRCA1 preneoplastic signature. Laser capture microdissection of frozen sections was used to isolate neoplastic cells or histologically normal fallopian tube epithelium, and expression profiles were generated on Affymetrix U133 Plus 2.0 gene expression arrays. Normal-risk controls were 11 women wild type for BRCA1 and BRCA2 (WT-FT). WT-FT were compared with histologically normal fallopian tube epithelium from seven women with deleterious BRCA1 mutations who had foci of at least intraepithelial neoplasm within their fallopian tube (B1-FTocc). WT-FT samples were also compared with 12 BRCA1 ovarian carcinomas (B1-CA). The comparison of WT-FT versus B1-FTocc resulted in 152 differentially expressed probe sets, and the comparison of WT-FT versus B1-CA resulted in 4079 differentially expressed probe sets. The BRCA1 preneoplastic signature was composed of the overlap between these two lists, which included 41 concordant probe sets. Genes in the BRCA1 preneoplastic signature included several known tumor suppressor genes such as CDKN1C and EFEMP1 and several thought to be important in invasion and metastasis such as E2F3. The expression of a subset of genes was validated with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry.
在进行 BRCA1 基因突变携带者的预防性输卵管-卵巢切除术时,常可在输卵管中发现微小浸润性癌和高级别上皮内瘤变,这表明许多 BRCA1 突变型卵巢癌起源于输卵管上皮。我们假设 BRCA1 基因突变携带者的组织学正常输卵管上皮内的基因表达谱变化与 BRCA1 突变型卵巢癌的表达谱重叠,并代表 BRCA1 癌前病变的特征。我们使用激光捕获显微切割技术从冷冻切片中分离出肿瘤细胞或组织学正常的输卵管上皮,并在 Affymetrix U133 Plus 2.0 基因表达谱芯片上生成表达谱。正常风险对照为 11 名 BRCA1 和 BRCA2 野生型(WT-FT)女性。将 WT-FT 与 7 名 BRCA1 有害突变且输卵管内至少存在上皮内肿瘤病灶的女性(B1-FTocc)的组织学正常输卵管上皮进行比较。WT-FT 样本还与 12 例 BRCA1 卵巢癌(B1-CA)进行了比较。WT-FT 与 B1-FTocc 的比较产生了 152 个差异表达的探针集,WT-FT 与 B1-CA 的比较产生了 4079 个差异表达的探针集。BRCA1 癌前病变特征由这两个列表的重叠组成,其中包括 41 个一致的探针集。BRCA1 癌前病变特征中的基因包括几个已知的肿瘤抑制基因,如 CDKN1C 和 EFEMP1,以及几个被认为在侵袭和转移中重要的基因,如 E2F3。通过定量逆转录-聚合酶链反应和免疫组织化学验证了一部分基因的表达。